Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

OS Therapies (OSTX) News Today

OS Therapies logo
$2.48 +0.08 (+3.33%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$2.43 -0.05 (-2.18%)
As of 08/22/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

OSTX Latest News

OS Therapies (NYSE:OSTX) Earns "Buy" Rating from D. Boral Capital
August 22 at 10:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/os-therapies-nyseostx-earns-buy-rating-from-d-boral-capital-2025-08-20/
OS Therapies Inc Reports Q2 2025 Earnings: Net Loss Per Share at $0.19, Revenue Details Unavailable
August 19, 2025  |  gurufocus.comhttps://www.gurufocus.com/news/3068508/os-therapies-inc-reports-q2-2025-earnings-net-loss-per-share-at-019-revenue-details-unavailable
Earnings Outlook For OS Therapies
August 18, 2025  |  benzinga.comhttps://www.benzinga.com/insights/earnings/25/08/47188268/earnings-outlook-for-os-therapies
OS Therapies Updates Quorum Rules for Shareholder Meetings
August 15, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/os-therapies-updates-quorum-rules-for-shareholder-meetings?utm_source=marketbeat.com&utm_medium=referral
OS Therapies Delays Q2 2025 Financial Report
August 15, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/os-therapies-delays-q2-2025-financial-report?utm_source=marketbeat.com&utm_medium=referral
OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent ...
August 9, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/os-therapies-announces-statistically-significant-130000203.html
OS Therapies files to sell 3.76M shares of common stock for holders
August 6, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/os-therapies-files-to-sell-376m-shares-of-common-stock-for-holders/ar-AA1JU3jg
OS Therapies Inc News (OSTX) - Investing.com
July 18, 2025  |  investing.comhttps://www.investing.com/equities/os-therapies-news/5
OS Therapies Inc. (NYSE-A: OSTX) Makes Important Strides in Rare Cancer Therapy
July 14, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GetNews/33382261/os-therapies-inc-nyse-a-ostx-makes-important-strides-in-rare-cancer-therapy/
OS Therapies Raises $4.2M Through Warrant Exercise
July 14, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/os-therapies-raises-4-2m-through-warrant-exercise?utm_source=marketbeat.com&utm_medium=referral
OS Therapies Inc.: Promising Cancer Immunotherapy and Strategic Regulatory Advancements Support Buy Rating
July 11, 2025  |  tipranks.comhttps://www.tipranks.com/news/ratings/os-therapies-inc-promising-cancer-immunotherapy-and-strategic-regulatory-advancements-support-buy-rating-ratings?utm_source=marketbeat.com&utm_medium=referral
Analysts Conflicted on These Healthcare Names: OS Therapies Incorporated (OSTX), Korro Bio (KRRO) and Veeva Systems (VEEV)
July 3, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VEEV/pressreleases/33145485/analysts-conflicted-on-these-healthcare-names-os-therapies-incorporated-ostx-korro-bio-krro-and-veeva-systems-veev/
OSTX - OS Therapies Inc Executives - Morningstar
July 3, 2025  |  morningstar.comM
OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
July 3, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250703693366/en/os-therapies-granted-end-of-phase-2-meeting-by-us-fda-for-ost-her2-program-in-the-prevention-or-delay-of-recurrent-fully-resected-pulmonary-metastatic-osteosarcoma/
Positive Buy Rating for OS Therapies Driven by Promising Phase 2b Trial Results and Regulatory Progress
July 2, 2025  |  tipranks.comhttps://www.tipranks.com/news/ratings/positive-buy-rating-for-os-therapies-driven-by-promising-phase-2b-trial-results-and-regulatory-progress-ratings?utm_source=marketbeat.com&utm_medium=referral
OS Therapies' (OSTX) "Buy" Rating Reaffirmed at D. Boral Capital
June 30, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/os-therapies-ostx-buy-rating-reaffirmed-at-d-boral-capital-2025-06-30/
OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor ...
June 30, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/os-therapies-presents-statistically-significantly-100000954.html
OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference
June 30, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250630174522/en/os-therapies-presents-statistically-significantly-positive-1-year-event-free-survival-overall-survival-and-safety-clinical-data-updates-for-ost-her2-at-the-mib-agents-factor-osteosarcoma-conference/
OS Therapies Stock Surges 12.4% After Positive FDA Feedback on OST-HER2
June 24, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/os-therapies-stock-surges-12-4-after-positive-fda-feedback-on-ost-her2/ar-AA1HkHKW
OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
June 24, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250624414411/en/os-therapies-receives-positive-fda-meeting-feedback-on-regulatory-pathway-for-accelerated-approval-of-ost-her2-in-the-prevention-or-delay-of-recurrent-fully-resected-pediatric-lung-metastatic-osteosarcoma/
OS Therapies Announces Warrant Exercise Inducement & Exchange Offer
June 23, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250623789974/en/os-therapies-announces-warrant-exercise-inducement-exchange-offer/
OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
June 10, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/os-therapies-partners-with-eversana-for-the-us-commercialization-of-ost-her2-in-recurrent-fully-resected-pediatric-lung-metastatic-osteosarcoma-302477352.html
OSTX OS Therapies Incorporated
June 1, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/OSTX
Buy Rating for OS Therapies: Promising Developments and Strategic Positioning in Cancer Immunotherapy
May 21, 2025  |  tipranks.comhttps://www.tipranks.com/news/ratings/buy-rating-for-os-therapies-promising-developments-and-strategic-positioning-in-cancer-immunotherapy?utm_source=marketbeat.com&utm_medium=referral
OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update
May 16, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250516302762/en/os-therapies-reports-first-quarter-2025-financial-results-and-provides-business-update/
OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma
May 15, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/os-therapies-forms-subsidiary-os-100000684.html
OS Therapies Inc (NYSE:OSTX) Major Shareholder Shalom Auerbach Sells 82,000 Shares
May 10, 2025  |  insidertrades.comhttps://www.insidertrades.com/alerts/nyse-ostx-insider-buying-and-selling-2025-05-10/
OS Therapies Inc sees $163,918 in stock sales by major shareholder
May 9, 2025  |  investing.comhttps://www.investing.com/news/insider-trading-news/os-therapies-inc-sees-163918-in-stock-sales-by-major-shareholder-93CH-4037667
OS Therapies secures patent for cancer immunotherapy tech
May 8, 2025  |  investing.comhttps://www.investing.com/news/company-news/os-therapies-secures-patent-for-cancer-immunotherapy-tech-93CH-4028441
Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies
May 2, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250502321412/en/emmy-winning-series-debuts-trailer-for-shelter-me-the-cancer-pioneers-offering-a-hopeful-look-at-breakthrough-cancer-therapies/
OS Therapies granted FDA meeting for OST-HER2
April 22, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/os-therapies-granted-fda-meeting-for-ost-her2-1034608629
OS Therapies FDA Meeting Request Granted
April 22, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250422058584/en/os-therapies-fda-meeting-request-granted/
OS Therapies Inc (NYSE:OSTX) Major Shareholder Sells $67,516.20 in Stock
April 12, 2025  |  insidertrades.comhttps://www.insidertrades.com/alerts/nyse-ostx-insider-buying-and-selling-2025-04-12/
OS Therapies Announces Positive Data From The Study Of OST-HER2 In Osteosarcoma In Dogs
April 12, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/os-therapies-announces-positive-data-study-ost-her2-osteosarcoma-dogs
OS Therapies Inc: Shalom Auerbach sells $81,566 in common stock
April 11, 2025  |  investing.comhttps://www.investing.com/news/insider-trading-news/os-therapies-inc-shalom-auerbach-sells-81566-in-common-stock-93CH-3982385
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
April 10, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250410123762/en/os-therapies-announces-positive-data-for-ost-her2-in-the-treatment-of-unresected-osteosarcoma-in-dogs-opening-the-potential-for-use-as-front-line-therapy-in-humans/
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals
April 9, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250409331328/en/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals/
Lake Street Initiates Coverage of OS Therapies (OSTX) with Buy Recommendation
April 3, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/lake-street-initiates-coverage-of-os-therapies-ostx-with-buy-recommendation/ar-AA1Ccle2
OS Therapies Inc Reports 2024 Net Loss Per Share of $0. ...
April 1, 2025  |  gurufocus.comhttps://www.gurufocus.com/news/2759368/os-therapies-inc-reports-2024-net-loss-per-share-of-088-amid-strategic-investments-and-ipo-expenses
OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update
March 31, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250331497947/en/OS-Therapies-Reports-Full-Year-2024-Financial-Results-and-Provides-Business-Update/
OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma
March 31, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250331351474/en/os-therapies-provides-regulatory-update-on-rare-pediatric-cancer-immunotherapy-candidate-ost-her2-for-human-osteosarcoma/
OS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
March 25, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/os-therapies-ost-her2-immunotherapy-114000250.html
OS Therapies' OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
March 25, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250325194230/en/os-therapies%e2%80%99-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers/
OS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to Analysts
March 23, 2025  |  insidermonkey.comhttps://www.insidermonkey.com/blog/os-therapies-ostx-among-the-penny-stocks-with-huge-upside-potential-according-to-analysts-1489562/
OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference
March 21, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250321978468/en/os-therapies-to-attend-the-jones-healthcare-and-technology-innovation-conference/
OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference
March 13, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250313374522/en/os-therapies-awarded-ost-her2-clinical-trial-data-presentation-at-mib-agents-factor-osteosarcoma-conference/
OS Therapies schedules Scientific Advice Meeting for OST-HER2 in Q3
March 11, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/os-therapies-schedules-scientific-advice-meeting-for-ost-her2-in-q3-1034463654
Spin-Offs as Catalysts: Unlocking Value, Driving Growth, and Creating Opportunities for Big Gains
March 4, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GetNews/31226596/spin-offs-as-catalysts-unlocking-value-driving-growth-and-creating-opportunities-for-big-gains/
Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27
February 26, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/join-os-therapies-exclusive-live-210100765.html
Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on February 27
February 26, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250226496977/en/join-os-therapies%e2%80%99-exclusive-live-investor-webinar-and-qa-session-on-february-27/
Get OS Therapies News Delivered to You Automatically

Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter.

OSTX Media Mentions By Week

OSTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

OSTX
News Sentiment
▼
0.11

0.69
▲
Average
Medical
News Sentiment

OSTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

OSTX Articles
This Week
▼
4

2
▲
OSTX Articles
Average Week

Get OS Therapies News Delivered to You Automatically

Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies
Headlines Tools

This page (NYSE:OSTX) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners
Nations are at war over what’s in this box
A resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...
Behind the Markets | Sponsoredtc pixel
GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...
Priority Gold | Sponsoredtc pixel
“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...
InvestorPlace | Sponsoredtc pixel
Cover all your expenses with just $118,000 invested?
Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...
Investors Alley | Sponsoredtc pixel
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsoredtc pixel
Man Who Called Nvidia at $1.10 Says Buy This Now...
In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...
The Oxford Club | Sponsoredtc pixel
Trump’s “new dollar” could shock Americans
"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...
Stansberry Research | Sponsoredtc pixel
Here's the last trade you should make before heading out for the weekend tomorrow.
On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...
Timothy Sykes | Sponsoredtc pixel